Stephens Inc. AR acquired a new stake in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,270 shares of the specialty pharmaceutical company’s stock, valued at approximately $299,000.

Several other institutional investors have also recently made changes to their positions in VRX. Gruss & Co. Inc. acquired a new stake in shares of Valeant Pharmaceuticals International in the first quarter valued at $104,000. Harbor Advisors LLC acquired a new stake in shares of Valeant Pharmaceuticals International in the first quarter valued at $110,000. WMS Partners LLC acquired a new stake in shares of Valeant Pharmaceuticals International in the first quarter valued at $116,000. PNC Financial Services Group Inc. lifted its holdings in shares of Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 2,763 shares during the period. Finally, Baird Financial Group Inc. acquired a new stake in shares of Valeant Pharmaceuticals International in the first quarter valued at $127,000. Institutional investors and hedge funds own 50.47% of the company’s stock.

In other news, Director Schutter Richard U. De purchased 10,000 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were bought at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the acquisition, the director now directly owns 77,479 shares in the company, valued at approximately $1,110,274.07. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (NYSE VRX) opened at 14.01 on Friday. The firm’s market capitalization is $4.88 billion. The firm has a 50-day moving average price of $14.22 and a 200 day moving average price of $13.18. Valeant Pharmaceuticals International, Inc. has a 12 month low of $8.31 and a 12 month high of $27.84.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.88) earnings per share. On average, equities analysts forecast that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Stephens Inc. AR Invests $299,000 in Valeant Pharmaceuticals International, Inc. (VRX)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/stephens-inc-ar-invests-299000-in-valeant-pharmaceuticals-international-inc-vrx/1582152.html.

Several analysts have recently weighed in on the company. HC Wainwright restated a “hold” rating and issued a $17.00 price objective on shares of Valeant Pharmaceuticals International in a report on Monday, September 18th. Piper Jaffray Companies restated a “sell” rating and issued a $14.00 price objective on shares of Valeant Pharmaceuticals International in a report on Sunday, September 17th. Vetr upgraded Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $12.46 price objective for the company in a report on Monday, September 18th. ValuEngine lowered Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $23.00 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $17.62.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.